Breakthrough Therapy Approved for Severe Alopecia Areata Treatment

Breakthrough Therapy for Severe Alopecia Areata Gains Regulatory Approval

The UK's Medicines and Healthcare products Regulatory Agency has granted marketing authorization to deuruxolitinib, a novel treatment developed by Sun Pharma UK, for the management of severe alopecia areata in adults.

This chronic autoimmune disorder is characterized by an aberrant immune response that triggers inflammation within hair follicles, leading to progressive hair loss on various body regions.

Deuruxolitinib exerts its therapeutic effect by selectively inhibiting a subset of Janus kinase (JAK) enzymes involved in the inflammatory cascade, thereby reducing hair follicle inflammation and promoting regrowth

Efficacy was demonstrated in two pivotal clinical trials involving 1,223 adult patients with alopecia areata who had experienced significant hair loss for at least six months.

Patients received either a fixed dose of deuruxolitinib or placebo for 24 weeks. The results showed that individuals treated with the new therapy exhibited superior scalp hair regrowth compared to those receiving the placebo

A notable proportion of patients achieved substantial hair restoration, with approximately 30% experiencing ≥80% scalp hair coverage after 24 weeks and around 23% achieving ≥90% hair regrowth within the same timeframe.

• Julian Beach, MHRA Executive Director for Healthcare Quality and Access stated: “This approval offers a new treatment option for adults struggling with severe alopecia areata.”
• The regulatory agency will continue to monitor the safety and efficacy profile of deuruxolitinib through ongoing post-marketing surveillance.